Section Arrow
STOK.NASDAQ
- Stoke Therapeutics
Quotes are at least 15-min delayed:2026/11/04 17:03 EST
After Hours
Last
 27.45
0 (0.00%)
Bid
26.91
Ask
27.49
High 27.45 
Low 27.45 
Volume 21.08K 
Regular Hours (Closed)
Last
 27.45
+0.46 (+1.70%)
Day High 
27.75 
Prev. Close
26.99 
1-M High
27.52 
Volume 
1.15M 
Bid
26.91
Ask
27.49
Day Low
26.6 
Open
27.75 
1-M Low
22.05 
Market Cap 
1.74B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 26.05 
20-SMA 25.18 
50-SMA 27.21 
52-W High 40.22 
52-W Low 21.81 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.39/-3.53
Enterprise Value
1.74B
Balance Sheet
Book Value Per Share
5.46
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
184.42M
Operating Revenue Per Share
0.14
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.11+0.3961+55.48%0.2PE
After Hours 1.04 -0.07 -6.31%
KPTIKaryopharm Therapeutics Inc.0.0729-0.0154-17.44%-- 
After Hours 0.0761 +0.0032 +4.39%
GERNGeron Corp1.08+0.15+16.13%-- 
After Hours 1.07 -0.01 -0.93%
INOInovio Pharmaceuticals1.62-0.04-2.41%-- 
After Hours 1.6115 -0.0085 -0.52%
RXRXRecursion Pharmaceuticals3.88+0.2+5.43%-- 
After Hours 3.8608 -0.0192 -0.49%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. Thecompany provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.